DUBLIN, Mar 07, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017" report to their offering.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2010.
There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.
This report contains a comprehensive listing of all joint venture deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
- Trends in joint venture dealmaking in the biopharma industry since 2010
- Analysis of joint venture deal structure
- Case studies of real-life joint venture deals
- Comprehensive listing of joint venture deals since 2010
- Access to joint venture contract documents
- The leading joint venture deals by value since 2010
- Most active joint venture dealmakers since 2010
- The leading joint venture partnering resources
In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 available deals and contracts are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
For more information about this report visit http://www.researchandmarkets.com/research/s2xt7s/global_joint
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-joint-venture-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2010-2017---research-and-markets-300419248.html
SOURCE Research and Markets